Posted on July 31st, 2010 by Health News
Intra-Cellular Therapies, Inc. announced the results from a Phase Ib/II clinical trial in patients with schizophrenia with ITI-007, the Company’s unique, investigational new drug for the treatment of schizophrenia. The trial met its primary endpoint demonstrating that ITI-007 was safe and well-tolerated in patients with stabilized schizophrenia…
No Comments »
Filed under: Pharmacy News
Posted on July 31st, 2010 by Health News
Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced that six of six patients (100%) in the ANA598 200 mg twice daily (bid) arm who were randomized to stop all treatment at Week 24 in an ongoing Phase II trial maintained undetectable levels of virus 12 weeks after stopping treatment, referred to as Sustained Virological Response 12, or [...]
No Comments »
Filed under: Pharmacy News
Posted on July 31st, 2010 by Health News
Shionogi Inc., a U.S.-based group company of Shionogi & Co., Ltd., announced the U.S. Food and Drug Administration approval of CUVPOSA™ (glycopyrrolate), the first liquid treatment for patients ages 3-16 who suffer from chronic severe drooling associated with neurologic conditions such as cerebral palsy. CUVPOSA™ was designated an Orphan Drug by the FDA…
No Comments »
Filed under: Pharmacy News
Posted on July 31st, 2010 by Health News
Much like two children in the back seat of a car, it can be challenging to get two catalysts to cooperate for the greater good. Now Northwestern University chemists have gotten two catalysts to work together on the same task — something easily done by nature but a difficult thing to do in the laboratory…
No Comments »
Filed under: Pharmacy News
Posted on July 31st, 2010 by Health News
GlaxoSmithKline announced today that the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER) has released the first lots of FluLaval® [Influenza Virus Vaccine] allowing distribution in the U.S. to begin for the 2010-2011 flu season. GSK anticipates distribution of Fluarix® [Influenza Virus Vaccine] to follow in the next several weeks.
No Comments »
Filed under: Pharmacy News
Posted on July 31st, 2010 by Health News
Endo Pharmaceuticals today reported financial results for the second quarter 2010. Total revenues during the second quarter of 2010 increased 6 percent to $396.5 million, compared with $373.1 million in the same quarter of 2009. Net income for the three months ended June 30, 2010 was $51.5 million, compared with $30.0 million in the [...]
No Comments »
Filed under: Pharmacy News
Posted on July 31st, 2010 by Health News
Cancer Research UK’s Drug Development Office marks the launch of its Biotherapeutics Development Unit (BDU) today (Friday) with the manufacture of its first product - an antibody for treating a range of cancers.
No Comments »
Filed under: Pharmacy News
Posted on July 31st, 2010 by Health News
Anadys Pharmaceuticals, Inc. today announced that six of six patients (100%) in the ANA598 200 mg twice daily (bid) arm who were randomized to stop all treatment at Week 24 in an ongoing Phase II trial maintained undetectable levels of virus 12 weeks after stopping treatment, referred to as Sustained Virological Response 12, or SVR12.
No Comments »
Filed under: Pharmacy News
Posted on July 31st, 2010 by Health News
This year “India has reported the lowest number of polio cases in [the] January-June period … in a decade,” PTI/ZeeTV reports. Twenty-four cases were detected between January and June this year, compared to 151 in the corresponding 2009 period, and 317 in January-June 2008 (7/29).
No Comments »
Filed under: Pharmacy News
Posted on July 31st, 2010 by Health News
Amgen reported adjusted earnings per share (EPS) of $1.38 for the second quarter of 2010, an increase of 7 percent compared to $1.29 for the second quarter of 2009. Adjusted net income increased 1 percent to $1,326 million for the second quarter of 2010 compared to $1,311 million for the second quarter of 2009.
No Comments »
Filed under: Pharmacy News
